US to no longer dis­trib­ute Eli Lil­ly’s bam­lanivimab alone due to coro­n­avirus vari­ants

The US gov­ern­ment and Eli Lil­ly agreed to halt all dis­tri­b­u­tion of the com­pa­ny’s Covid-19 mon­o­clon­al an­ti­body bam­lanivimab as of Wednes­day due to the “sus­tained in­crease” of coro­n­avirus vari­ants in the US.

All treat­ment de­liv­ery sites will con­tin­ue to be able to or­der Lil­ly’s com­bo Covid-19 treat­ment of bam­lanivimab and ete­se­vimab, to be ad­min­is­tered to­geth­er, or Re­gen­eron’s an­ti­body cock­tail, the as­sis­tant sec­re­tary for pre­pared­ness and re­sponse (AS­PR) and FDA said. Both of the treat­ments from Lil­ly and Re­gen­eron have proven to be use­ful among peo­ple who have Covid-19 but are not hos­pi­tal­ized.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.